ESMO 2018 - Postconference Report

09 November 2018

This report compiles our on-the-ground coverage of the European Society of Medical Oncology (ESMO) Congress 2018, including exclusive breaking news and KOL-based analysis.

A sampling of headlines:

• Tesaro’s TSR-042 lacks key differentiation from Merck’s Keytruda despite significant endometrial cancer results, experts say
• MacroGenics inclined to shift margetuximab from second-line to first-line in gastric cancer, decisions likely after full Phase II data at ASCO GI 2019, source says
• AstraZeneca’s Lynparza likely to overtake Roche’s Avastin in dominance of ovarian cancer maintenance setting; PAOLA-1 study a strong influence on PARP inhibitor outlook, experts say
• Halozyme enrols 150 out of 570 patients for Phase III PEGPH20 trial in first-line pancreatic cancer, source says